Johannes M. Waldschmidt

Author

University Medical Center Freiburg ORCID

Also Known As

J Waldschmidt, J. M Waldschmidt, J. Waldschmidt, J.M. Waldschmidt, Johannes M Waldschmidt, Johannes M. Waldschmidt, Johannes Moritz Waldschmidt, Johannes Waldschmidt

198

Publications

674

Citations

H-Index

Concepts

All Affiliations

University Medical Center Freiburg University of Freiburg Dana-Farber Cancer Institute Harvard University Universitätsklinikum Würzburg

About

Johannes M. Waldschmidt is an author at University Medical Center Freiburg specializing in medicine, tumor biology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	119
2	Cell Biology	2	2	68
3	Immunology	2	2	93
4	Immunotherapy	2	2	93
5	Pathology	1	1	26

Johannes M. Waldschmidt

Publications

360

Citations

H-Index

Page 1

	Year	Citations
<scp>CXCL</scp>12 and <scp>CXCR</scp>7 are relevant targets to reverse cell adhesion‐mediated drug resistance in multiple myeloma Johannes M. Waldschmidt, Anna Simon, Dagmar Wider, British Journal of Haematology	2017	74
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years Monika Engelhardt, Gabriele Ihorst, Ola Landgren, Haematologica	2015	51
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma Julia Frede, Praveen Anand, Noori Sotudeh, Nature Cell Biology Hematological MalignancyImmunotherapeutic VulnerabilitiesImmunologyMyelopoiesisImmunotherapy	2021	51
Potent <i>in vitro</i> and <i>in vivo</i> activity of sorafenib in multiple myeloma: induction of cell death, <scp>CD</scp>138‐downregulation and inhibition of migration through actin depolymerization Josefina Udi, Julia Schüler, Dagmar Wider, British Journal of Haematology Hematological MalignancyPlasma CellsMalignant Blood DisorderImmunologyCell Death	2013	42
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma Mara John, Moutaz Helal, Johannes Duell, Blood	2024	42
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i> -Mutated Multiple Myeloma Johannes M. Waldschmidt, Jake A. Kloeber, Praveen Anand, Clinical Cancer Research	2021	38
Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma Johannes M. Waldschmidt, Andrew J. Yee, Tushara Vijaykumar, Leukemia Hematological MalignancyMedicinePathologyTreatment FailureCell Biology	2022	26
Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients Veronika Riebl, Sandra Maria Dold, Dagmar Wider, Frontiers in Oncology	2021	13
Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma Johannes M. Waldschmidt, Stefan J. Fruttiger, Dagmar Wider, Journal of Cancer Research and Clinical Oncology	2022	13
ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease Kristina Maas‐Bauer, A. Stell, Kaili Yan, Nature Communications	2024	10

Page 1